Moderna Sees Key Role For Respiratory Vaccines As COVID-19 Goes Endemic
Executive Summary
The company anticipates another year of big sales for its COVID-19 vaccine, but is also touting a pipeline of 44 programs in development, with oncology and possibly rare disease data this year.
You may also be interested in...
Beyond COVID-19 Spending Growth, Biosimilars Slowed Growth In Other Categories
The COVID-19 windfall meant a 12% rise in spending on medicines in the US in 2021 versus 2020, but just 5% excluding COVID, which is expected to fall to 1%-4% compound annual growth through 2026.
Eiger Has Positive Data For Its COVID-19 Drug, But Faces Uncertain Market
Peginterferon lambda helped reduce hospitalizations and deaths among high-risk COVID-19 patients in a Phase III trial.
Co-Inventor Of mRNA Tech Goes After Sickle Cell Anemia
After a chance encounter at a photocopy machine brewed the recipe for Pfizer and Moderna’s success with mRNA vaccines, Dr Drew Weissman has set sights on developing a single-injection therapy for sickle cell anemia.